RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer
Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival....
Gespeichert in:
Veröffentlicht in: | Clinical science (1979) 2020-07, Vol.134 (14), p.1973-1990 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1990 |
---|---|
container_issue | 14 |
container_start_page | 1973 |
container_title | Clinical science (1979) |
container_volume | 134 |
creator | Wang, Huaiming Huang, Rongkang Guo, Wentai Qin, Xiusen Yang, Zifeng Yuan, Zixu Wei, Yingqi Mo, Chunlin Zeng, Zhantao Luo, Jian Cai, Jian Wang, Hui |
description | Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC. |
doi_str_mv | 10.1042/CS20191174 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1042_CS20191174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32677671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</originalsourceid><addsrcrecordid>eNpF0E1Lw0AQBuBFFFurF3-A7FmM7mc2OZbQqlAUbD2HyWbbriSbsrsq_fcm1g_mMMPw8B5ehC4puaVEsLtiyQjNKVXiCI2pUCTJFE-P0ZhQwRPJGB2hsxDeCGG8n1M04ixVKlV0jD5fnqZJZV1t3QbvfBeNdbiYLeYUG7cFp03A2jQNbu3GQ7Sdu8HWfUD4vsDVWG9N23kTbIgDx9UeR_AbE4fE2WrJeo911_RGR2iwHpQ_RydraIK5-NkT9DqfrYqHZPF8_1hMF4lmgsdEm1xwqDMBmZRVnYta5rVIaaYyrbMUKml4rgklUoi8krT_GE5ACck0aAA-QdeHXO27ELxZlztvW_D7kpJyaK_8b6_HVwe8e69aU__R37r4F3V_alA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</title><source>MEDLINE</source><source>Portland Press Electronic Journals</source><creator>Wang, Huaiming ; Huang, Rongkang ; Guo, Wentai ; Qin, Xiusen ; Yang, Zifeng ; Yuan, Zixu ; Wei, Yingqi ; Mo, Chunlin ; Zeng, Zhantao ; Luo, Jian ; Cai, Jian ; Wang, Hui</creator><creatorcontrib>Wang, Huaiming ; Huang, Rongkang ; Guo, Wentai ; Qin, Xiusen ; Yang, Zifeng ; Yuan, Zixu ; Wei, Yingqi ; Mo, Chunlin ; Zeng, Zhantao ; Luo, Jian ; Cai, Jian ; Wang, Hui</creatorcontrib><description>Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.</description><identifier>ISSN: 0143-5221</identifier><identifier>EISSN: 1470-8736</identifier><identifier>DOI: 10.1042/CS20191174</identifier><identifier>PMID: 32677671</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Antineoplastic Agents ; Carcinogenesis ; CELF1 Protein - metabolism ; Cell Movement ; Colorectal Neoplasms - metabolism ; Drug Resistance, Neoplasm ; Epithelial-Mesenchymal Transition ; Female ; HCT116 Cells ; HT29 Cells ; Humans ; Male ; Mice ; Mice, Nude ; Middle Aged ; Oxaliplatin ; Proto-Oncogene Protein c-ets-2 - genetics ; Proto-Oncogene Protein c-ets-2 - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Clinical science (1979), 2020-07, Vol.134 (14), p.1973-1990</ispartof><rights>2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</citedby><cites>FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</cites><orcidid>0000-0003-0086-5795</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3253,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32677671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Huaiming</creatorcontrib><creatorcontrib>Huang, Rongkang</creatorcontrib><creatorcontrib>Guo, Wentai</creatorcontrib><creatorcontrib>Qin, Xiusen</creatorcontrib><creatorcontrib>Yang, Zifeng</creatorcontrib><creatorcontrib>Yuan, Zixu</creatorcontrib><creatorcontrib>Wei, Yingqi</creatorcontrib><creatorcontrib>Mo, Chunlin</creatorcontrib><creatorcontrib>Zeng, Zhantao</creatorcontrib><creatorcontrib>Luo, Jian</creatorcontrib><creatorcontrib>Cai, Jian</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</title><title>Clinical science (1979)</title><addtitle>Clin Sci (Lond)</addtitle><description>Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.</description><subject>Animals</subject><subject>Antineoplastic Agents</subject><subject>Carcinogenesis</subject><subject>CELF1 Protein - metabolism</subject><subject>Cell Movement</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Drug Resistance, Neoplasm</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Female</subject><subject>HCT116 Cells</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Middle Aged</subject><subject>Oxaliplatin</subject><subject>Proto-Oncogene Protein c-ets-2 - genetics</subject><subject>Proto-Oncogene Protein c-ets-2 - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0143-5221</issn><issn>1470-8736</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1Lw0AQBuBFFFurF3-A7FmM7mc2OZbQqlAUbD2HyWbbriSbsrsq_fcm1g_mMMPw8B5ehC4puaVEsLtiyQjNKVXiCI2pUCTJFE-P0ZhQwRPJGB2hsxDeCGG8n1M04ixVKlV0jD5fnqZJZV1t3QbvfBeNdbiYLeYUG7cFp03A2jQNbu3GQ7Sdu8HWfUD4vsDVWG9N23kTbIgDx9UeR_AbE4fE2WrJeo911_RGR2iwHpQ_RydraIK5-NkT9DqfrYqHZPF8_1hMF4lmgsdEm1xwqDMBmZRVnYta5rVIaaYyrbMUKml4rgklUoi8krT_GE5ACck0aAA-QdeHXO27ELxZlztvW_D7kpJyaK_8b6_HVwe8e69aU__R37r4F3V_alA</recordid><startdate>20200731</startdate><enddate>20200731</enddate><creator>Wang, Huaiming</creator><creator>Huang, Rongkang</creator><creator>Guo, Wentai</creator><creator>Qin, Xiusen</creator><creator>Yang, Zifeng</creator><creator>Yuan, Zixu</creator><creator>Wei, Yingqi</creator><creator>Mo, Chunlin</creator><creator>Zeng, Zhantao</creator><creator>Luo, Jian</creator><creator>Cai, Jian</creator><creator>Wang, Hui</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-0086-5795</orcidid></search><sort><creationdate>20200731</creationdate><title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</title><author>Wang, Huaiming ; Huang, Rongkang ; Guo, Wentai ; Qin, Xiusen ; Yang, Zifeng ; Yuan, Zixu ; Wei, Yingqi ; Mo, Chunlin ; Zeng, Zhantao ; Luo, Jian ; Cai, Jian ; Wang, Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antineoplastic Agents</topic><topic>Carcinogenesis</topic><topic>CELF1 Protein - metabolism</topic><topic>Cell Movement</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Drug Resistance, Neoplasm</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Female</topic><topic>HCT116 Cells</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Middle Aged</topic><topic>Oxaliplatin</topic><topic>Proto-Oncogene Protein c-ets-2 - genetics</topic><topic>Proto-Oncogene Protein c-ets-2 - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Huaiming</creatorcontrib><creatorcontrib>Huang, Rongkang</creatorcontrib><creatorcontrib>Guo, Wentai</creatorcontrib><creatorcontrib>Qin, Xiusen</creatorcontrib><creatorcontrib>Yang, Zifeng</creatorcontrib><creatorcontrib>Yuan, Zixu</creatorcontrib><creatorcontrib>Wei, Yingqi</creatorcontrib><creatorcontrib>Mo, Chunlin</creatorcontrib><creatorcontrib>Zeng, Zhantao</creatorcontrib><creatorcontrib>Luo, Jian</creatorcontrib><creatorcontrib>Cai, Jian</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical science (1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Huaiming</au><au>Huang, Rongkang</au><au>Guo, Wentai</au><au>Qin, Xiusen</au><au>Yang, Zifeng</au><au>Yuan, Zixu</au><au>Wei, Yingqi</au><au>Mo, Chunlin</au><au>Zeng, Zhantao</au><au>Luo, Jian</au><au>Cai, Jian</au><au>Wang, Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</atitle><jtitle>Clinical science (1979)</jtitle><addtitle>Clin Sci (Lond)</addtitle><date>2020-07-31</date><risdate>2020</risdate><volume>134</volume><issue>14</issue><spage>1973</spage><epage>1990</epage><pages>1973-1990</pages><issn>0143-5221</issn><eissn>1470-8736</eissn><abstract>Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.</abstract><cop>England</cop><pmid>32677671</pmid><doi>10.1042/CS20191174</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-0086-5795</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0143-5221 |
ispartof | Clinical science (1979), 2020-07, Vol.134 (14), p.1973-1990 |
issn | 0143-5221 1470-8736 |
language | eng |
recordid | cdi_crossref_primary_10_1042_CS20191174 |
source | MEDLINE; Portland Press Electronic Journals |
subjects | Animals Antineoplastic Agents Carcinogenesis CELF1 Protein - metabolism Cell Movement Colorectal Neoplasms - metabolism Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition Female HCT116 Cells HT29 Cells Humans Male Mice Mice, Nude Middle Aged Oxaliplatin Proto-Oncogene Protein c-ets-2 - genetics Proto-Oncogene Protein c-ets-2 - metabolism Xenograft Model Antitumor Assays |
title | RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T14%3A18%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RNA-binding%20protein%20CELF1%20enhances%20cell%20migration,%20invasion,%20and%20chemoresistance%20by%20targeting%20ETS2%20in%20colorectal%20cancer&rft.jtitle=Clinical%20science%20(1979)&rft.au=Wang,%20Huaiming&rft.date=2020-07-31&rft.volume=134&rft.issue=14&rft.spage=1973&rft.epage=1990&rft.pages=1973-1990&rft.issn=0143-5221&rft.eissn=1470-8736&rft_id=info:doi/10.1042/CS20191174&rft_dat=%3Cpubmed_cross%3E32677671%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32677671&rfr_iscdi=true |